 | This article may be confusing or unclear to readers. (October 2019) |
| Company type | Public limited company |
|---|---|
| Industry | Biotechnology |
| Founded | October 2000 |
| Defunct | May 2011 |
| Headquarters | , |
Key people | Mark Ferguson (CEO) |
Number of employees | 110 |
| Website | Archived 24 July 2013 at the Wayback Machine |
Renovo Group plc was a biopharmaceutical company, which was founded in 1998 and was headquartered in Manchester, United Kingdom. It worked in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.[1] Renovo does not currently have any marketed products. It aimed "to be first to market with a scar prevention pharmaceutical drug in the US and Europe" in approximately 2014. Following the failure of its last clinical candidate Juvista, all 100 of Renovo's staff were laid off in 2011.[2][3][4]
Although the company stopped all pharmaceutical development it continued as a financial provider. In August 2014, Renovo Group plc was renamed Inspired Capital plc.[5][6]
- ^ London Regenerative Medicine Network – January 2007 Meeting Archived 28 September 2007 at the Wayback Machine
- ^ Renovo Group founder to become Science Foundation Ireland's boss (9 January 2012). Manchester Evening News.
- ^ Pharma Times Just 10% of workforce left at Renovo after Juvista failure (4 March 2011). Pharmatimes.com.
- ^ Grogan, Kevin (31 May 2001). "Future bleak for Renovo with no workers or products". PharmaTimes. Retrieved 14 December 2016.
- ^ Rename Plan for Renovo (16 July 2014). InsiderMedia.com
- ^ "Company Overview of Inspired Capital plc". Bloomberg. Retrieved 14 December 2016.